Nanogen to Acquire Syn X Pharma in CA$16.3M Transaction

Feb 10, 2004

NEW YORK, Feb. 10 (GenomeWeb News) - Nanogen plans to acquire Syn X Pharma in an all-stock transaction, the company said today.

The transaction is valued at approximately CA$16.3 million ($12.3 million). Under the agreement, Nanogen will offer common shares to holders of Syn X common shares in a stock-for-stock exchange.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

In on the Action

NPR reports that with medical data being big business, some companies want to get patients involved.

What's in Store?

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

This Week in PNAS

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Warren Releases Genetic Ancestry Results

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Main menu